title: Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.
authors.forename: Orlane
authors.initials: O
authors.lastname: Vatel
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.|b INSERM U935 , Villejuif , France.
authors.forename: Cedric
authors.initials: C
authors.lastname: Aumont
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Mathy
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.
authors.forename: Morgane
authors.initials: M
authors.lastname: Petit
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.|b INSERM U935 , Villejuif , France.
authors.forename: Joffrey
authors.initials: J
authors.lastname: Feriel
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.|b INSERM U935 , Villejuif , France.
authors.forename: Ivan
authors.initials: I
authors.lastname: Sloma
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.|b INSERM U935 , Villejuif , France.
authors.forename: Annelise
authors.initials: A
authors.lastname: Bennaceur-Griscelli
authors.affiliation: a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.|b INSERM U935 , Villejuif , France.
authors.forename: Ali G
authors.initials: AG
authors.lastname: Turhan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count; D063926:Drug Hypersensitivity Syndrome / Q000175:diagnosis* / Q000209:etiology*; D057915:Drug Substitution; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl